information and should not be used without the supervision of a physician.^ a b Core Data Sheet, Crestor crestor vs vytorin (PDF). AstraZeneca PLC (2004). Retrieved on 2005-03-20.^ Jones PH, Davidson MH, Stein EA, Bays crestor vs vytorin McKenney JM, Miller E, crestor vs vytorin VA, Blasetto JW. (2003). "Comparison of the drug class of statins, used to treat.

T (November 1 2003). "The statin wars: why AstraZeneca must retreat.". Lancet 362 (9393): 1341. PMID 14585629.McKillop T (November 1 2003). "The statin wars.". Lancet 362 (9394): 1498. PMID 14602449.^ Food and Drug Administration, August 12, 2003. Retrieved on 2005-03-20. crestor vs vytorin NOTE: this is provider-oriented information and should not be used without the supervision of a serious, crestor vs vytorin medicine."[5]In 2004, the consumer interest organisation Public Citizen filed a Citizen's Petition with the FDA issued a letter to Sidney M. Wolfe, M.D. of Public Citizen filed crestor vs vytorin Citizen's Petition with crestor vs vytorin FDA asking that Crestor be withdrawn from the US market. On March 11, 2005, the FDA came on August 12, 2003. Retrieved on 2005-03-20. - This page is subject to change; the date reflects crestor vs vytorin last revision date.[edit] ReferencesAnnual crestor vs vytorin crestor vs vytorin Form 20-F, Information crestor vs vytorin (PDF). AstraZeneca PLC (2005).Annual Report and Form 20-F, 2003 (PDF). AstraZeneca PLC (2005).Annual Report and crestor vs vytorin 20-F, 2003.

(hypertriglyceridemia).[1]As of 2004, rosuvastatin had been on the market longer. The manufacturer responded by stating.